» Articles » PMID: 38366144

Proteomic and Transcriptomic Profiling of Brainstem, Cerebellum and Olfactory Tissues in Early- and Late-phase COVID-19

Abstract

Neurological symptoms, including cognitive impairment and fatigue, can occur in both the acute infection phase of coronavirus disease 2019 (COVID-19) and at later stages, yet the mechanisms that contribute to this remain unclear. Here we profiled single-nucleus transcriptomes and proteomes of brainstem tissue from deceased individuals at various stages of COVID-19. We detected an inflammatory type I interferon response in acute COVID-19 cases, which resolves in the late disease phase. Integrating single-nucleus RNA sequencing and spatial transcriptomics, we could localize two patterns of reaction to severe systemic inflammation, one neuronal with a direct focus on cranial nerve nuclei and a separate diffuse pattern affecting the whole brainstem. The latter reflects a bystander effect of the respiratory infection that spreads throughout the vascular unit and alters the transcriptional state of mainly oligodendrocytes, microglia and astrocytes, while alterations of the brainstem nuclei could reflect the connection of the immune system and the central nervous system via, for example, the vagus nerve. Our results indicate that even without persistence of severe acute respiratory syndrome coronavirus 2 in the central nervous system, local immune reactions are prevailing, potentially causing functional disturbances that contribute to neurological complications of COVID-19.

Citing Articles

Microglia dysfunction, neurovascular inflammation and focal neuropathologies are linked to IL-1- and IL-6-related systemic inflammation in COVID-19.

Fekete R, Simats A, Biro E, Posfai B, Cserep C, Schwarcz A Nat Neurosci. 2025; 28(3):558-576.

PMID: 40050441 PMC: 11893456. DOI: 10.1038/s41593-025-01871-z.


Plasma proteomic evidence for increased β-amyloid pathology after SARS-CoV-2 infection.

Duff E, Zetterberg H, Heslegrave A, Dehghan A, Elliott P, Allen N Nat Med. 2025; .

PMID: 39885359 DOI: 10.1038/s41591-024-03426-4.


A Primer on Proteomic Characterization of Intercellular Communication in a Virus Microenvironment.

Kostas J, Brainard C, Cristea I Mol Cell Proteomics. 2025; 24(3):100913.

PMID: 39862905 PMC: 11889360. DOI: 10.1016/j.mcpro.2025.100913.


Functional Connectivity Alterations Associated with COVID-19-Related Sleep Problems: A Longitudinal Resting-State fMRI Study.

Chen H, Li L, Sun Y, Liu Y, Chen W, Liu P Nat Sci Sleep. 2025; 17():97-113.

PMID: 39839964 PMC: 11748004. DOI: 10.2147/NSS.S488911.


A multi-tissue longitudinal proteomics study to evaluate the suitability of post-mortem samples for pathophysiological research.

Beusch C, Braesch-Andersen K, Felldin U, Sabatier P, Widgren A, Bergquist J Commun Biol. 2025; 8(1):78.

PMID: 39824970 PMC: 11742016. DOI: 10.1038/s42003-025-07515-z.


References
1.
Mao L, Jin H, Wang M, Hu Y, Chen S, He Q . Neurologic Manifestations of Hospitalized Patients With Coronavirus Disease 2019 in Wuhan, China. JAMA Neurol. 2020; 77(6):683-690. PMC: 7149362. DOI: 10.1001/jamaneurol.2020.1127. View

2.
Schweitzer F, Kleineberg N, Goreci Y, Onur O, Franke C, Warnke C . Neuro-COVID-19 is more than anosmia: clinical presentation, neurodiagnostics, therapies, and prognosis. Curr Opin Neurol. 2021; 34(3):423-431. DOI: 10.1097/WCO.0000000000000930. View

3.
Romero-Sanchez C, Diaz-Maroto I, Fernandez-Diaz E, Sanchez-Larsen A, Layos-Romero A, Garcia-Garcia J . Neurologic manifestations in hospitalized patients with COVID-19: The ALBACOVID registry. Neurology. 2020; 95(8):e1060-e1070. PMC: 7668545. DOI: 10.1212/WNL.0000000000009937. View

4.
Paterson R, Brown R, Benjamin L, Nortley R, Wiethoff S, Bharucha T . The emerging spectrum of COVID-19 neurology: clinical, radiological and laboratory findings. Brain. 2020; 143(10):3104-3120. PMC: 7454352. DOI: 10.1093/brain/awaa240. View

5.
Aschman T, Mothes R, Heppner F, Radbruch H . What SARS-CoV-2 does to our brains. Immunity. 2022; 55(7):1159-1172. PMC: 9212726. DOI: 10.1016/j.immuni.2022.06.013. View